Holen Sie sich die Stockscreener-App
164.76
0.26%
-0.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$164.95
Offen:
$163.4
24-Stunden-Volumen:
2.01M
Relative Volume:
0.71
Marktkapitalisierung:
$255.54B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
49.48
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
+4.63%
1M Leistung:
+0.00%
6M Leistung:
-19.43%
1J Leistung:
+104.32%
1-Tages-Spanne:
$161.47
$164.83
1-Wochen-Bereich:
$154.53
$165.91
52-Wochen-Spanne:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
164.77 | 255.82B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,271.68 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.81 | 658.89B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.23 | 470.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.22 | 375.50B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.19 | 304.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca (AZN) Results Check: EPS Prints Above Forecast on the Day; Market Reaction: The Market Price Advances 3.03% at the CloseEarnings Season Outlook - Vinanet
7,500 Shares in Astrazeneca Plc $AZN Bought by Westport Asset Management Inc. - MarketBeat
AstraZeneca PLC : Goldman Sachs reaffirms its Buy rating - marketscreener.com
Is It Too Late to Buy AstraZeneca PLC (AZN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send? - TradingKey
AstraZeneca Expands Respiratory Pipeline With New China Trial for Chronic Lung Infections - TipRanks
Rumors of AstraZeneca-Bristol-Myers merger fade; focus shifts to each firm's strengths in cancer and immune diseases. - Pluang
AstraZeneca (AZN) CFO’s share award vests at £114.60 a share - Stock Titan
AstraZeneca Vs. Bristol-Myers Squibb: Who’s The Better Bargain For Investors (NYSE:BMY) - Seeking Alpha
Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig - European Biotechnology Magazine
Is AstraZeneca (LSE:AZN) Becoming the Quiet Anchor of a Jittery London Market? - Kalkine Media
Why Is Large Pharmaceutical Pipelines During Broader Market Uncertainty Active In London Today? - Kalkine Media
AstraZeneca CFO Receives First Vesting Under Long-Term Performance Share Plan - TipRanks
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca PLC : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca PLC : UBS reiterates its Buy rating - marketscreener.com
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease - finance.biggo.com
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates - Proactive financial news
AstraZeneca stock edges higher as Q2 2026 growth and EPS gains offset lung cancer trial setback - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Anchoring London's Healthcare Trade Today? - Kalkine Media
AstraZeneca’s win in lung cancer; Sandoz inks a China deal - Yahoo Finance
Did AstraZeneca's (LSE:AZN) Lung Cancer Data Just Reset The Blue-Chip Mood Today? - Kalkine Media
AstraZeneca stock rises on lung cancer trial news - AD HOC NEWS
Can AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Turn Regulatory Review Into Durable Progress? - Kalkine Media
Can Shell (LSE:SHEL) And AstraZeneca (LSE:AZN) Turn Capital Allocation Into Durable Progress? - Kalkine Media
Health Care Down on Growth DoubtsHealth Care Roundup - marketscreener.com
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
These UK Stocks Are Undervalued After Earnings - Morningstar
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch - Yahoo Finance
AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda - finance.biggo.com
AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant - Yahoo Finance UK
AstraZeneca ditches lung cancer treatment trial - Yahoo Finance UK
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer - BioPharma Dive
UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials - marketscreener.com
AstraZeneca stock gains on lung cancer trial news - ad-hoc-news.de
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - Benzinga
Market Wrap: EU chip stocks surge on Anthropic's earnings! AstraZeneca halts trials for lung cancer therapy (17.08.2026) - XTB.com
AstraZeneca (AZN) drug delays progression in first-line HER2 lung cancer - Stock Titan
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda - Clinical Trials Arena
AstraZeneca (NYSE: AZN) halts lung trial after survival goals seen unlikely - Stock Titan
Lung cancer trial success puts AstraZeneca (AZN) drug duo in play - Stock Titan
Plato Investment Management Ltd Takes $5.90 Million Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca PLC : JP Morgan remains its Buy rating - marketscreener.com
AstraZeneca halts lung cancer trial in fresh pipeline setback - Proactive financial news
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update - marketscreener.com
FTSE 100 Gains Support From Miners, AstraZeneca And Rolls-Royce - DirectorsTalk Interviews
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 36.59% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca Stops Cancer Drug Trial as Success Seen Unlikely - Bloomberg.com
AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu - Yahoo Finance UK
AstraZeneca halts lung trial as two cancer drugs show positive results - marketscreener.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):